DekaBank Deutsche Girozentrale Raises Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

DekaBank Deutsche Girozentrale lifted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,453 shares of the biopharmaceutical company’s stock after acquiring an additional 2,546 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Halozyme Therapeutics were worth $2,963,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of HALO. TD Asset Management Inc increased its holdings in Halozyme Therapeutics by 517.0% during the 4th quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after purchasing an additional 1,662,390 shares during the period. Norges Bank acquired a new stake in Halozyme Therapeutics in the fourth quarter valued at approximately $44,935,000. Epoch Investment Partners Inc. raised its holdings in Halozyme Therapeutics by 250.5% in the fourth quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after acquiring an additional 831,199 shares in the last quarter. Boston Trust Walden Corp purchased a new position in Halozyme Therapeutics in the second quarter worth approximately $23,211,000. Finally, Swedbank AB acquired a new position in Halozyme Therapeutics during the 1st quarter worth approximately $13,927,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $62.31 on Thursday. The stock has a market cap of $7.93 billion, a P/E ratio of 25.75, a P/E/G ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a twelve month low of $32.83 and a twelve month high of $65.53. The stock has a 50 day moving average of $58.14 and a two-hundred day moving average of $48.95. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. During the same quarter in the prior year, the firm earned $0.68 EPS. Halozyme Therapeutics’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 3.7 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Benchmark reaffirmed a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price target on shares of Halozyme Therapeutics in a report on Friday, September 13th. Morgan Stanley increased their price objective on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. decreased their target price on Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Finally, The Goldman Sachs Group increased their price target on shares of Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.44.

Insider Transactions at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at approximately $803,876.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Matthew L. Posard sold 9,881 shares of the firm’s stock in a transaction on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the completion of the sale, the director now owns 69,874 shares in the company, valued at approximately $4,031,729.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, June 27th. The shares were sold at an average price of $51.93, for a total transaction of $519,300.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $803,876.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 84,881 shares of company stock worth $4,888,184. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.